Petros Grivas MD, PhD

Articles

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

October 28th 2024

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

October 28th 2024

Panelists discuss how the SPLASH trial investigating 177Lu-PNT2002 demonstrates promising efficacy in treating advanced cancer through targeted radionuclide therapy.

Key Takeaways and Looking Ahead

October 28th 2024

Panelists discuss how recent advancements in targeted therapies and a multidisciplinary approach can significantly enhance the management and care of patients with metastatic prostate cancer.

Use of Bone Protection Agents

October 21st 2024

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

October 21st 2024

Panelists discuss how the ARANOTE trial exploring darolutamide in combination with androgen deprivation therapy shows potential benefits in managing advanced prostate cancer.

Genetic Testing – Somatic

October 14th 2024

Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

October 14th 2024

Genetic Testing – Germline

October 7th 2024

Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.

Recent Data on ARPI-Based Combination Regimens

October 7th 2024

Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.

Treatment Timelines Related to Disease State and Use of Monotherapy

September 30th 2024

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

Treatment Landscape and Sequencing of Therapies

September 30th 2024

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Park and Grivas Expand on Treatment Updates in Bladder Cancer

August 7th 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Dr Grivas on Key Updates in Genitourinary Cancer Management

June 17th 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

Exploring Newly Released Data in GU and GI Cancers: Drs Grivas and Marshall

June 3rd 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Grivas on Frontline Treatment Options in Metastatic RCC

April 12th 2024

Petros Grivas, MD, PhD, discusses frontline treatment options for patients with metastatic renal cell carcinoma.

Dr Grivas on Future Directions for Adjuvant Therapy Research in RCC

April 4th 2024

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

Dr Grivas on Updated Data in the Treatment of Metastatic/Unresectable Urothelial Carcinoma

February 8th 2024

Petros Grivas, MD, PhD, discusses 2023 updates regarding the treatment of patients with metastatic/unresectable urothelial carcinoma.

Dr Grivas on Key Data From the CheckMate 901 Trial in Urothelial Cancer

January 10th 2024

Petros Grivas, MD, PhD, discusses outcomes associated with the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

May 18th 2023

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

May 18th 2023

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.